To include your compound in the COVID-19 Resource Center, submit it here.

AGS-003: Additional Phase II data

Additional data from an ongoing, open-label Phase II trial in 21 newly diagnosed metastatic RCC patients with an unfavorable prognosis

Read the full 206 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE